Changes in the serum levels of brain-derived neurotrophic factor in adults with attention deficit hyperactivity disorder after treatment with atomoxetine

@article{RamosQuiroga2013ChangesIT,
  title={Changes in the serum levels of brain-derived neurotrophic factor in adults with attention deficit hyperactivity disorder after treatment with atomoxetine},
  author={Josep Antoni Ramos-Quiroga and Margarida Corominas-Roso and Gl{\`o}ria Palomar and N{\'u}ria G{\'o}mez-Barros and Marta Ribas{\'e}s and Cristina S{\'a}nchez-Mora and Rosa Bosch and Mariana Lima Nogueira and Montserrat Corrales and Sergi Valero and Miquel Casas},
  journal={Psychopharmacology},
  year={2013},
  volume={231},
  pages={1389-1395}
}
Atomoxetine (ATX) is a non-stimulant drug approved for the treatment of attention deficit hyperactivity disorder (ADHD). Although animal models have provided evidence that brain-derived neurotrophic factor (BDNF) is involved in the effects of ATX in the brain, there are no studies of BDNF in ADHD patients undergoing treatment with ATX. The aim of this study… CONTINUE READING